Amur Minerals Corporation (GB:CRTX)
LSE:CRTX
Top Page
Amur Minerals
(LSE:CRTX)
Select Model
Select Model
Rating:47Neutral
Price Target:
12.50 p
▲(25.00% Upside)
Action:ReiteratedDate:02/03/26
The score is held back primarily by weak financial fundamentals (very small revenue with ongoing losses and negative free cash flow), despite improved loss/cash-burn trends and a debt-free balance sheet. Technically, momentum is positive, but the very high RSI suggests near-term overextension. Valuation remains unattractive/unclear due to negative earnings and no indicated dividend support.
Positive Factors
Conservative leverage
A debt-free 2024 balance sheet materially reduces fixed financing obligations and default risk, preserving strategic optionality. For a loss-making company, low leverage lengthens time to next financing and lowers cash interest burden, a durable reduction in financial vulnerability.
Negative Factors
Very small revenue and negative free cash flow
Extremely low sales combined with persistent negative operating and free cash flow demonstrate the business is not self‑funding. Over time this forces recurring external financing, increases dilution risk, and limits the firm's ability to invest in R&D or commercial scale‑up.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
A debt-free 2024 balance sheet materially reduces fixed financing obligations and default risk, preserving strategic optionality. For a loss-making company, low leverage lengthens time to next financing and lowers cash interest burden, a durable reduction in financial vulnerability.
Read all positive factors
Amur Minerals (CRTX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£5.69M
Dividend YieldN/A
Average Volume (3M)84.04K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding51,735,268
10 Day Avg. Volume114,469
30 Day Avg. Volume84,037
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.57
Price to Sales (P/S)33.47
P/FCF Ratio-0.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Amur Minerals Business Overview & Revenue Model
Company Description
CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin ...
How the Company Makes Money
null...
Amur Minerals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 25.00K | 57.37K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.12K | 21.00K | 16.57K | 0.00 | 0.00 | -3.90K |
| EBITDA | -1.24M | -566.00K | -2.26M | -1.81M | -1.30M | -3.08M |
| Net Income | -1.28M | -607.00K | -9.65M | -2.45M | -1.54M | -2.08M |
Balance Sheet | ||||||
| Total Assets | 2.38M | 1.82M | 4.79M | 23.89M | 23.06M | 23.71M |
| Cash, Cash Equivalents and Short-Term Investments | 479.03K | 1.28M | 4.38M | 2.90M | 4.93M | 2.79M |
| Total Debt | 0.00 | 0.00 | 888.54K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 583.34K | 341.00K | 662.00K | 765.65K | 832.07K | 771.06K |
| Stockholders Equity | 1.80M | 1.48M | 4.12M | 23.13M | 30.11M | 31.35M |
Cash Flow | ||||||
| Free Cash Flow | -1.19M | -961.00K | -2.77M | -2.99M | -1.40M | -2.12M |
| Operating Cash Flow | -1.19M | -933.00K | -2.77M | -2.73M | -1.10M | -1.68M |
| Investing Cash Flow | -91.96K | 2.33M | 34.93M | -511.00K | 6.04M | -5.18M |
| Financing Cash Flow | 0.00 | -67.00K | -31.45M | 968.00K | 0.00 | 9.89M |
Amur Minerals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £5.69M | -1.04 | -78.00% | ― | ― | ― | |
44 Neutral | £36.20M | -0.94 | -18.30% | ― | ― | ― | |
43 Neutral | £8.92M | -4,173.96 | -433.59% | ― | ― | ― | |
42 Neutral | £4.96M | -5.98 | -153.80% | ― | ― | -616.67% |
* Healthcare Sector Average
GB:CRTX
Amur Minerals
11.00
1.50
15.79%
GB:NFX
Nuformix Plc
0.19
0.07
55.74%
GB:CIZ
Cizzle Biotechnology Holdings PLC
2.25
0.70
45.16%
GB:ROQ
Roquefort Investments PLC
8.50
-8.00
-48.48%
Amur Minerals Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
CRISM Wins FDA Orphan Drug Status for Glioma ChemoSeed Programme
Positive
Mar 17, 2026
CRISM Therapeutics has secured Orphan Drug Designation from the U.S. FDA for irinotecan to treat malignant glioma, expanding beyond glioblastoma to cover all high-grade gliomas and marking a key regulatory and commercial milestone for its irinotec...
Business Operations and StrategyProduct-Related Announcements
CRISM Therapeutics Wins Key Japanese Patent for ChemoSeed Cancer Implant
Positive
Jan 20, 2026
CRISM Therapeutics has secured a Japanese patent for its lead product ChemoSeed, covering both the manufacturing processes and therapeutic use of irinotecan-based biodegradable chemotherapeutic implants, particularly for treating brain tumours suc...
Business Operations and StrategyPrivate Placements and Financing
CRISM Therapeutics Reveals Updated Major Shareholders After December Fundraising
Neutral
Jan 9, 2026
CRISM Therapeutics has published the results of an independent analysis of its shareholder register as at 31 December 2025, identifying five significant shareholders each holding at least 3% of its ordinary share capital, with CEO Andrew Webb the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.